How to manage hyperglycemia in an acute coronary syndrome patient

Current Treatment Options in Cardiovascular Medicine

Volumn 15, Issue 1, 2013, Pages 93-103

  Vivas, David ^a   Bernardo, Esther ^a   Palacios Rubio, Julian ^a   Fernández Ortiz, Antonio ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; Diabetes mellitus; Hyperglycemia; Insulin; Oral antidiabetic drugs; Platelets; Thrombosis

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLICLAZIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; POTASSIUM; REPAGLINIDE; SIXAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ACUTE CORONARY SYNDROME; ARTHRALGIA; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DOSE CALCULATION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; EVIDENCE BASED MEDICINE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INTENSIVE CARE UNIT; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; LIVER DISEASE; LOW DRUG DOSE; MEDITERRANEAN DIET; MORTALITY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

EID: 84873077754     PISSN: 10928464     EISSN: 15343189     Source Type: Journal    
DOI: 10.1007/s11936-012-0215-4     Document Type: Article

References (66)

1. Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773-8.
2. Norhammar AM, Ryden L, Malmberg K. Admission plasma glucose. Independent risk factor for long-term prognosis after myocardial infarction even in nondiabetic patients. Diabetes Care. 1999;22:1827-31.
3. Wahab NN, Cowden EA, Pearce NJ, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748-54.
4. Petursson P, Herlitz J, Caidahl K, et al. Admission glycaemia and outcome after acute coronary syndrome. Int J Cardiol. 2007;116:315-20.
5. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117:1610-9.
6. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implication for patients with and without recognized diabetes. Circulation. 2005;111:3078-86.
7. Wahab NN, Cowden EA, Pearce NJ, ICONS Investigators, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol. 2002;40:1748-54.
8. Vivas D, García-Rubira JC, González-Ferrer JJ, et al. Prognostic value of first fasting glucose measurement compared with admission glucose level in patients with acute coronary syndrome. Rev Esp Cardiol. 2008;61:458-64.
9. Suleiman M, Hammerman H, Boulos M, et al. Fasting glucose is an important independent risk factor for 30-d mortality in patients with acute myocardial infarction: a prospective study. Circulation. 2005;111:754-60.
10. Goyal A, Mahaffey KW, Garg J, et al. Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. Eur Heart J. 2006;27:1289-97.
11. Bilotta F, Rosa G. Glycemia management in critical care patients. World J Diabetes. 2012;3:130-4.
12. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36:3008-13.
13. Ishihara M, Kagawa E, Inoue I, et al. Impact of admission hyperglycemia and diabetes mellitus on short- and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol. 2007;99:1674-9.
14. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med. 2007;35(Suppl):508-18.
15. Andrews RC, Walker BR. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci. 1999;96:513-23.
16. Lang CH. Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol. 1992;263:703-11.
17. Dimitriadis G, Leighton B, Parry-Billings M, et al. Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J. 1997;321:707-12.
18. Lang CH, Dobrescu C, Mészáros K. Insulin-mediated glucose uptake by individual tissues during sepsis. Metabolism. 1990;39:1096-107.
19. Fan J, Li YH, Wojnar MM, et al. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock. 1996;6:164-70.
20. Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. Am J Med. 2002;112:305-11.
21. Ling P, Smith R, Bistrian B. Hyperglycemia enhances the cytokine production and oxidative responses to a low but not high dose of endotoxin in rats. Crit Care Med. 2005;33:1084-9.
22. Yu WK, Li WQ, Li N, et al. Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counter-regulatory hormone concentrations. World J Gastroenterol. 2003;9:1824-7.
23. Stentz FB, Umpierrez GE, Cuervo R, et al. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-86.
24. Morohoshi M, Fujisawa K, Uchimura I, et al. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 1996;45:954-9.
25. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067-72.
26. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262:157-72.
27. Nieuwdorp M, Stroes ES, Meijers JC, et al. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol. 2005;5:155-9.
28. Mansfield MW, Grant PJ. Fibrinolysis and diabetic retinopathy in NIDDM. Diabetes Care. 1995;18:1577-81.
29. Vaidyula VR, Boden G, Rao AK. Platelet and monocyte activation by hyperglycemia and hyperinsulinemia in healthy subjects. Platelets. 2006;17:577-85.
30. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol. 2003;41:1013-20.
31. Oswald GA, Smith CC, Delamothe AP, et al. Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction. Br Heart J. 1988;59:663-71.
32. Aoki I, Shimoyama K, Aoki N, et al. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes. J Am Coll Cardiol. 1996;27:560-6.
33. Verkleij CJ, Bruijn RE, Meesters EW, et al. The hemostatic system in patients with type 2 diabetes with and without cardiovascular disease. Clin Appl Thromb Hemost. 2011;6:57-63.
34. Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282-91.
35. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol. 2006;48:298-304.
36. Vivas D, Garcia-Rubira JC, Bernardo E, et al. Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndrome. Results of the CHIPS study. Heart. 2011;97:803-9.
37. Yang SW, Zhou YJ, Hu DY, et al. Association between admission hypoglycemia and in-hospital and 3-year mortality in older patients with acute myocardial infarction. Heart. 2010;96:1444-50.
38. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
39. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 1997;96:1152-6.
40. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group. Circulation. 1998;98:2227-34.
41. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-67.
42. Van der Horst IC, Zijlstra F. van't Hof AW, et al. Glucose-insulin- potassium infusion in patients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 2003;42:784-91.
43. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA. 2005;293:437-46.
44. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-61. This study randomized 1253 patients to: intensive IV insulin (24 h) followed by SC insulin vs IV insulin (24 h) only vs conventional treatment. In this trial, authors did not find significant differences among patients with an intensive insulin therapy and conventional treatment.
45. Timmer JR, Svilaas T, Ottervanger JP, et al. Glucose-insulin-potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS)-II. J Am Coll Cardiol. 2006;47:1730-1.
46. Cheung NW, Wong VW, McLean M. The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction. Diabetes Care. 2006;29:765-70.
47. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-61.
48. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA. 2007;298:2399-405.
49. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-39.
50. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008;300:933-44.
51. Finfer S, Chittock DR, Su SY, et al. Intensive vs conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-97. One of the most important clinical trials to manage hyperglycemia in critically ill patients. This study randomized 6104 patients to: Intensive IV insulin therapy (glucose 81-108 mg/dL) vs conventional treatment (glucose <180 mg/dL). Primary endpoint (mortality at 90 d) was significantly higher in the intensive group (27.5% vs 24.9%, P = 0.02).
52. Selker HP, Beshansky JR, Sheehan PR, et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA. 2012;307:1925-33. Recent clinical trial that randomized 911 patients to: Prehospital GIK therapy vs placebo. Study was unable to detect significant differences in the primary endpoint (progression to myocardial infarction).
53. Steg G, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 (in press).
54. Hamm W, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting without ST-segment elevation. Eur Heart J. 2011;32:2999-3054.
55. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012;33:1635-701.
56. Goyal A, Nerenberg K, Gerstein HC, et al. Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomized trials with important clinical end points. Diabetes Vasc Dis Res. 2008;5:276-84.
57. Vergès B, Avignon A, Bonnet F, et al. Consensus statement on the care of the hyperglycemic/diabetic patient during and in the immediate follow-up of acute coronary syndrome. Diabetes Metab. 2012;38:113-27. A current consensus statement of the French Cardiovascular Society. This manuscript is a practical approach to the management of hyperglycemia in patients with ACS. Most of the recommendations are by expert consensus.
58. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892-9.
59. Mellbin LG, Malmberg K, Norhammar A, et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J. 2008;29:166-76.
60. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21:220-9.
61. Collaborative ADVANCE Group. Effects of intensive blood glucose control on vascular outcomes in patients with type 2 diabetes mellitus: results of the ADVANCE trial. N Engl J Med. 2008;358:2560-72.
62. Zeller M, Danchin N, Simon D, et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab. 2010;95:4993-5002.
63. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10-6.
64. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: a randomized controlled trial. Lancet. 2005;366:1279-89.
65. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like Peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011;2011:215764.
66. Monami M, Iacomelli I, Marchionni N, et al. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2010;20:224-35.